(Q33858767)

29 July 2017

3 references

12 March 2019

13 March 2019

17 June 2019

Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review (English)

1 reference

29 July 2017

3 references

12 March 2019

13 March 2019

17 June 2019

3 references

12 March 2019

13 March 2019

17 June 2019

Sue Langham

1

1 reference

29 July 2017

Julia Langham

series ordinal

2

1 reference

29 July 2017

Hans-Peter Goertz

series ordinal

3

1 reference

29 July 2017

Mark Ratcliffe

series ordinal

4

1 reference

29 July 2017

language of work or name

1 reference

31 March 2011

4 references

BMC Medical Research Methodology

29 July 2017

12 March 2019

13 March 2019

17 June 2019

4 references

29 July 2017

12 March 2019

13 March 2019

17 June 2019

11

1 reference

29 July 2017

page(s)

32

1 reference

Creative Commons Attribution 2.0 Generic

29 July 2017

copyright license

3 references

12 March 2019

13 March 2019

on focus list of Wikimedia project

17 June 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2288-11-32

0 references

cites work

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Quality of life of psoriasis patients before and after balneo -- or balneophototherapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Improved survival in psoriatic arthritis with calendar time

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Reader's guide to critical appraisal of cohort studies: 1. Role and design

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Large-scale observational studies of hypericum extracts in patients with depressive disorders--a systematic review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

British Society for Rheumatology Biologics Register

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Remission in psoriatic arthritis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

The risk of melanoma in association with long-term exposure to PUVA.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Psoriasis causes as much disability as other major medical diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Malignant tumours and psoriasis: a follow-up study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Why we need observational studies to evaluate the effectiveness of health care

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Psoriatic arthritis. Historical background and epidemiology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Skin tumors in the European PUVA Study. Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Long-term follow-up of skin cancer in the PUVA-48 cooperative study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

An Italian study on psoriasis and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Role of depression in quality of life for patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

The direct cost of care for psoriasis and psoriatic arthritis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

The risk of mortality in patients with psoriasis: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

De testimonio: on the evidence for decisions about the use of therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

National registries of systemic treatment for psoriasis and the European 'Psonet' initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-32

Clinical and genetic registries in psoriatic disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Relevance of the COBRA trial in current psoriasis practice

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

DANBIO: a nationwide registry of biological therapies in Denmark.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079698

Medication adherence and health care costs associated with biologics in Medicaid‐enrolled patients with psoriasis

29 October 2018

1 reference

12 December 2020

Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?

1 reference

12 December 2020

The impact of psoriasis on health care costs and patient work loss

1 reference

12 December 2020

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

1 reference

12 December 2020

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome

1 reference

12 December 2020

Cardiovascular morbidity in psoriatic arthritis

1 reference

12 December 2020

Prevalence of malignancy in psoriatic arthritis

1 reference

12 December 2020

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience

1 reference

12 December 2020

Determinants of quality of life in patients with psoriasis: A study from the US population

1 reference

12 December 2020

Development and early experiences of a Swedish psoriatic arthritis register

1 reference

12 December 2020

Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy

1 reference

12 December 2020

Description and prediction of physical functional disability in psoriatic arthritis: A longitudinal analysis using a Markov model approach

1 reference

12 December 2020

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

1 reference

12 December 2020

PUVA and cancer risk: the Swedish follow-up study

1 reference

12 December 2020

A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis--'DIP or not DIP revisited'

1 reference

12 December 2020

Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs

1 reference

12 December 2020

The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis

1 reference

12 December 2020

Progression in psoriatic arthritis: role of time varying clinical indicators

1 reference

12 December 2020

Clinical severity of psoriasis in last 20 years of PUVA study

1 reference

12 December 2020

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II)

1 reference

12 December 2020

Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study

1 reference

12 December 2020

Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices

1 reference

12 December 2020

Cardiovascular Disease, Cancer, and Cause of Death in Patients with Psoriasis: 10 Years Prospective Experience in a Cohort of 1,380 Patients

1 reference

12 December 2020

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

1 reference

12 December 2020

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis

1 reference

12 December 2020

Long-term use of psoralens and ultraviolet A for psoriasis: evidence for efficacy and cost savings

1 reference

12 December 2020

No long-term changes in psoriasis severity and quality of life following climate therapy

1 reference

12 December 2020

PsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectives

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2288-11-32

1 reference

Dimensions Publication ID

29 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2288-11-32

9 September 2019

1 reference

29 July 2017

1 reference